[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"International Peace Maternity and Child Health Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":141},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,41,62,87,114],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100587205","phase-2-ivig-trial-for-the-treatment-of-bronchopulmonary-dysplasia-100587205",false,"NCT06925360","IVIG Trial for the Treatment of Bronchopulmonary Dysplasia","The Efficacy of Intravenous Immunoglobulin for the Treatment of Bronchopulmonary Dysplasia","Inclusion Criteria:\n\n* Gestational age between 25 weeks and 29 weeks + 6 days\n* Admission within 24 hours after birth.\n* Clinical symptoms and chest X-ray results show a highly suspicion of BPD （Clinical symptoms and chest X-ray changes of BPD）.Clinical symptoms develop in several days or weeks after birth, including respiratory symptoms and signs such as shortness of breath, cyanosis or pulmonary rales, intermittent hypoxic attacks, and chronic oxygen dependence (increased oxygen concentration and assisted ventilation) .One of the following signs present in chest X-ray: lung texture thickening or ground glass opacity in early stage, diffuse lung texture blurred, lung hyperinflation, shadow of linear density increased, and shadow of triangular density increased under the pleura.\n* A normal full-term newborn without a history of severe lung diseases, birth asphyxia, hypoxic-ischemic encephalopathy or other conditions that may affect the development of the respiratory, nervous and other systems.\n\nExclusion Criteria:\n\n* Major congenital anomalies(e.g., congenital heart disease, congenital craniocerebral deformity, congenital structural abnormality of respiratory system, congenital hereditary metabolic disease)\n* Chromosomal defects (e.g., trisomy 13, 18, 21)\n* Severe intracranial hemorrhage\n* Multiple organ failure\n* With severe lung infections\n* Other circumstances that the investigator determines are not suitable for participation in this study",true,"ALL","10 Weeks",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","It is intended to examine the efficacy and safety of intravenous immunoglobulin(IVIG) for the bronchopulmonary dysplasia in preterms. Participants will received continuous infusion IVIG 1 g\u002Fkg\u002Fday for the first 2 days, 0.5 g\u002Fkg\u002Fday for next 3 days (total does 3.5 g\u002Fkg), repeatable if necessary.",[27],"Bronchopulmonary Dysplasia","RECRUITING","2026-05-22",{"date":31,"type":32},"2026-05-27","ACTUAL",{"date":34,"type":32},"2025-04-12",{"date":36,"type":21},"2027-12",{"name":38,"class":39},"International Peace Maternity and Child Health Hospital","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":16,"sex":17,"minAge":48,"maxAge":18,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":40},"100636087","phase-2-effects-of-ivig-for-bpd-in-preterm-infant-born-at-28-weeks-and-below-100636087","NCT07561125","Effects of IVIG for BPD in Preterm Infant Born at 28 Weeks and Below","The Short-term and Long-term Effects of IVIG for Bronchopulmonary Dysplasia in Preterm Infant Born at 28 Weeks and Below","Inclusion Criteria:\n\n* Gestational age ≤ 28 weeks + 6 days\n* Admission within 24 hours after birth.\n* Infants show a suspicion of BPD, the diagnosis is suspected based on the following clinical manifestations and chest X-ray findings.\n\nClinical manifestations: Respiratory symptoms such as tachypnea (rapid breathing) and cyanosis, requiring respiratory support (including invasive, non-invasive, or oxygen therapy) to maintain oxygen saturation.\n\nChest X-ray: Findings include increased bilateral lung markings or ground-glass opacities, and diffuse increased density in both lungs. Other possible causes such as infection or heart disease should be ruled out.\n\n• A normal full-term newborn without a history of severe lung diseases, birth asphyxia, hypoxic-ischemic encephalopathy or other conditions that may affect the development of the respiratory, nervous and other systems.\n\nExclusion Criteria:\n\n* Major congenital anomalies(e.g., congenital heart disease, congenital craniocerebral deformity, congenital structural abnormality of respiratory system, congenital hereditary metabolic disease)\n* Chromosomal defects (e.g., trisomy 13, 18, 21)\n* Severe intracranial hemorrhage\n* Multiple organ failure\n* With severe lung infections\n* Other circumstances that the investigator determines are not suitable for participation in this study","1 Day",{"count":50,"type":21},29,[24],"It is intended to examine the short-term and long-term efficacy and safety of intravenous immunoglobulin(IVIG) for the bronchopulmonary dysplasia in preterms born at 28 weeks and below. Participants will received continuous infusion IVIG 1 g\u002Fkg\u002Fday for the first 2 days, 0.5 g\u002Fkg\u002Fday for next 3 days (total does 3.5 g\u002Fkg), repeatable if necessary.",[27],"2026-04-26",{"date":56,"type":32},"2026-05-01",{"date":58,"type":21},"2026-04",{"date":60,"type":21},"2029-09",{"name":38,"class":39},{"id":63,"slug":64,"hasResults":11,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":4,"eligibilityCriteria":68,"healthyVolunteers":11,"sex":69,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":4,"studyType":74,"phases":4,"briefSummary":75,"conditions":76,"keywords":4,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":4},"100574453","study-of-laparoscopic-radical-hysterectomy-based-on-space-anatomy-in-patients-with-ib3-and-iia2-cervical-cancer-100574453","NCT06759480","Study of Laparoscopic Radical Hysterectomy Based on Space Anatomy in Patients With IB3 and IIA2 Cervical Cancer","Comparison Between Laparoscopic Radical Hysterectomy Based on Space Anatomy and Abdominal Radical Hysterectomy for Stage IB3 and IIA2 Cervical Cancer: a Multicenter Retrospective Cohort Study","Inclusion Criteria:\n\n1. Aged between 20 to 70 years\n2. Preoperative clinical diagnosis was FIGO 2018 stage IB3 or IIA2 cervical cancer;\n3. Patients who received standard Querleu-Morrow type C radical hysterectomy (including ARH or LRH based on space anatomy) and pelvic lymphadenectomy;\n4. no preoperative suspected lymph nodes metastasis, parametrial involvement or lower 1\u002F3 vagina involvement.\n\nExclusion Criteria:\n\n1. patients who had active double cancer or uncontrolled serious concurrent disease that might compromise prognosis;\n2. pregnancy;\n3. incomplete radical surgery;\n4. follow-up time less than 6 months or lost to follow-up","FEMALE","20 Years","70 Years",{"count":73,"type":21},500,"OBSERVATIONAL","Radical hysterectomy is an effect treatment for FIGO IB3 and IIA2 cervical cancer patients who refuse to receive radical concurrent chemoradiotherapy. However, due to the large tumor size, both patients and surgeons encountered the risk of substantial bleeding, urinary tract damage, and unsatisfactory resection during surgery. Therefore, the exploration of effective and safe surgical treatments is crucial in enhancing the quality of life and prognosis for patients. Laparoscopic radical hysterectomy (LRH) offers the advantages of reduced bleeding and accelerated recovery, thereby minimizing patient discomfort and enhancing their quality of life. However, the prognosis of patients who received LRH or traditional abdominal radical hysterectomy (ARH) remains controversial. We proposed a modified LRH skill based on new space anatomy concept. In our previous single-center study, the result demonstrates that LRH based on space anatomy leads to less intraoperative blood loss and decreased ureteral injury rate compared with traditional skill. The benefits of this new method for patient survival remain uncertain. In this multicenter retrospective study, we aim to assess clinical prognosis and safety of this new LRH compared with traditional abdominal radical hysterectomy (ARH) in FIGO IB3 and IIA2 cervical cancer.",[77],"Locally Advanced Cervical Cancer","NOT_YET_RECRUITING","2025-01-03",{"date":81,"type":32},"2025-01-06",{"date":83,"type":21},"2024-12-27",{"date":85,"type":21},"2025-03-15",{"name":38,"class":39},{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":93,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":69,"minAge":95,"maxAge":96,"enrollmentInfo":97,"targetDuration":4,"studyType":22,"phases":99,"briefSummary":101,"conditions":102,"keywords":104,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":4},"100562169","effectiveness-of-transvaginal-niche-resection-versus-expectant-management-in-patients-with-secondary-infertility-and-a-large-uterine-caesarean-scar-defect-100562169","NCT06599671","Effectiveness of Transvaginal Niche Resection Versus Expectant Management in Patients with Secondary Infertility and a Large Uterine Caesarean Scar Defect","Effectiveness of Transvaginal Niche Resection Versus Expectant Management in Patients with Secondary Infertility and a Large Uterine Caesarean Scar Defect (niche), a Randomised Controlled Trial","TVARES","Inclusion Criteria:\n\n1. It was diagnosed by MRI as a large niche (defined as niche with a depth of \\>50% of the myometrial thickness and a residual myometrial thickness (RMT) ≤3mm);\n2. Infertility secondary to niche (the inability to conceive within 12 months of unprotected intercourse or repeated failed IVF);\n3. Fertility requirements;\n4. Signed informed consent.\n\nExclusion Criteria:\n\n1. Age below 18 years or over 49 years;\n2. Contraindications for intraspinal or general anaesthesia;\n3. A (suspected) malignancy or combined benign lesions requiring hysterectomy;\n4. Atypical endometrial cells or cervical dysplasia;\n5. Uterine or cervical polyps;\n6. Submucosal fibroids;\n7. Hydrosalpinx.","19 Years","48 Years",{"count":98,"type":21},100,[100],"NA","The goal of this clinical trial is to evaluate the efficacy and safety of transvaginal niche resection in improving pregnancy outcomes of a large uterine caesarean scar defect (niche) with secondary infertility. The main questions it aims to answer are:\n\n1. Does transvaginal niche resection improve pregnancy outcomes of a large uterine caesarean scar defect (niche) with secondary infertility?\n2. What medical problems do participants have when taking transvaginal niche resection?\n\nResearchers will compare transvaginal niche resection to expectant management (without any additional surgical intervention) to see if transvaginal niche resection works to improve pregnancy outcomes of a large uterine caesarean scar defect (niche) with secondary infertility.\n\nParticipants will:\n\n1. Undergo a procedure (transvaginal niche resection) within 2 week after randomization in the intervention group. Women were advised to use contraception in the first 6 months following niche resection to allow uterine healing prior to subsequent pregnancy.\n2. Receive usual care at least 9 months which means no additional surgical intervention during this period in the control group. Patients are allowed to become pregnant and to receive fertility therapies if indicated. Any member of the control group who has not become pregnant after 9 months will be given the opportunity to undergo a transvaginal niche resection.\n3. Receive a standardized magnetic resonance imaging (MRI) evaluation of the niches. Niches will be evaluated at baseline in all groups and at 3 months after surgery.\n4. Be contacted by telephone at 6, 9 and 15 months to assess the primary and secondary outcomes.",[103],"Caesarean Scar Defect",[105],"caesarean scar defect","2024-09-21",{"date":108,"type":32},"2024-09-24",{"date":110,"type":21},"2024-10-01",{"date":112,"type":21},"2027-09-30",{"name":38,"class":39},{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":69,"minAge":4,"maxAge":121,"enrollmentInfo":122,"targetDuration":4,"studyType":22,"phases":124,"briefSummary":125,"conditions":126,"keywords":129,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":40},"100516559","the-effectiveness-of-the-letrozole-induced-endometrial-preparation-protocol-in-frozen-thawed-embryo-transfer-fet-100516559","NCT06006091","The Effectiveness of the Letrozole-induced Endometrial Preparation Protocol in Frozen-thawed Embryo Transfer (FET)","Clinical Outcomes of Letrozole-induced Endometrial Preparation Regimens Versus Conventional Endometrial Preparation Regimens Including Natural Cycle, Hormone Replacement Regimens in FET, a Randomized Controlled Study","Inclusion Criteria:\n\nWomen \\\u003C40 years of age undergoing IVF or ICSI at our reproductive center with a total of ≤3 superovulation cycles , and with ≥2 cleavage embryos or ≥1 blastocyst were cryopreserved. Previous cycles of embryo transfer ≤ 2 and only one transfer cycle with 1-2 embryos per study subject was enrolled.\n\nExclusion Criteria:\n\n1. Patients with chromosomal abnormalities in either spouse, hydrosalpinx, severe endometriosis, adenomyosis, and uterine and uterine cavity organic diseases such as uterine malformations, endometrial polyps, and uterine adhesions;\n2. patients who underwent pre-implantation genetic diagnosis (PGT);\n3. patients who underwent ICSI using surgically obtained epididymal or testicular spermatozoa;\n4. patients with a Body mass index (BMI, = weight\u002Fheight2 ) \\> 30 kg\u002Fm2;\n5. patients with recurrent spontaneous abortions;\n6. patients with sequential embryo transfer.","40 Years",{"count":123,"type":21},858,[100],"The goal of this single center, non-blinded, randomized controlled clinical trial to comparison of pregnancy outcomes and perinatal outcomes in patients undergoing IVF treatment (including ICSI) with FET with letrozole-induce endothelial preparation protocol versus natural cycles, hormone replacement protocol.\n\nThe main questions it aims to answer are:\n\n* To investigate whether letrozole-induce endothelial preparation is effective in improving the live birth rate and clinical pregnancy rate.\n* To explore its possible impact on clinically important indicators such as spontaneous abortion rate, implantation cycle cancellation rate, days of endothelial preparation, and number of visits to the clinic.\n\nThe study subjects were randomized into groups starting at D1-D3 of the menstrual cycle. The study subjects were stratified according to whether their menstrual cycles were regular or not, and were divided into the following endothelial preparation regimens according to the pre-prepared stratified zoned randomized group numbers: (1) regular menstrual cycles (25-35 d): letrozole ovulation-promoting cycles, natural cycles, and hormone-replacement cycles; and (2) irregular menstrual cycles (\\\u003C25 d or \\>35 d): letrozole ovulation-promoting cycles, hormone-replacement cycle.",[127,128],"Letrozole","Infertility, Female",[130,131,132],"Frozen-thawed embryo transfer","Letroziole","Endothelial preparation protocol","2023-08-16",{"date":135,"type":32},"2023-08-23",{"date":137,"type":32},"2023-08-01",{"date":139,"type":21},"2027-08-01",{"name":38,"class":39},""]